Overview

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Phase:
PHASE1
Details
Lead Sponsor:
GigaGen, Inc.